Alaunos Therapeutics Releases Early Data on ALN1003
Alaunos Therapeutics announced early data from two non-Good Laboratory Practice diet-induced obesity mouse studies evaluating ALN1003, the company's lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease. ALN1003 is an oral small-molecule drug being developed for a non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. We conducted two separate studies using a standard diet-induced obesity mouse model in male C57BL/6 mice maintained on a high-fat diet. Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, decreases in liver injury enzymes and other liver-related biomarker, and improvement in metabolic biomarkers. Collectively, these findings suggest encouraging metabolic effects of ALN1003 in the DIO model.
Trade with 70% Backtested Accuracy
Analyst Views on TCRT
About TCRT
About the author
Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data
- Significant Drug Effects: Alaunos Therapeutics' ALN1003 demonstrated a mean weight loss of up to -12.9% in diet-induced obesity mouse studies, indicating potential as a new treatment option for obesity.
- Liver Health Improvement: The drug reduced liver weight by 43% compared to untreated mice, highlighting its effectiveness and potential to lower the risk of obesity-related liver diseases.
- Biochemical Indicator Improvement: Long-term administration of ALN1003 was associated with significant reductions in ALT, AST, and ALP levels, along with a trend toward lower total bilirubin, suggesting its potential in improving metabolic health.
- Future Development Plans: The company plans to pursue additional financing to support ongoing preclinical work for ALN1003 and optimize manufacturing processes, ensuring drug efficacy and safety to pave the way for future IND applications.
Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential
- Significant Weight Loss: In the DIO mouse model, ALN1003-treated mice exhibited an average weight reduction of -12.9%, indicating the drug's potential efficacy in obesity treatment.
- Liver Health Improvement: ALN1003 reduced liver weight by 43% and lowered liver injury biomarkers such as ALT and AST, suggesting a positive impact on metabolic-associated liver disease.
- Reduced Food and Water Intake: The ALN1003 treatment group consumed significantly less food (347.5g/cage vs 425.0g/cage), which may correlate with the drug's weight loss mechanism, further supporting its potential as a non-hormonal treatment.
- Ongoing R&D Plans: Alaunos is focused on conducting additional preclinical studies and optimizing manufacturing processes to advance ALN1003, aiming to provide a new non-hormonal treatment option for obesity patients.
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.
Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
PMGC Capital's Acquisition: PMGC Capital LLC announced its acquisition of 83,500 shares (approximately 5.09%) in Alaunos Therapeutics, indicating a belief that the company is undervalued and has potential for growth.
Strategic Engagement Plans: PMGC Capital intends to engage with Alaunos' management to explore strategic opportunities such as mergers, acquisitions, or partnerships, while commending Alaunos for its financial stewardship.
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024
Earnings Report: Alaunos Therapeutics reported a second quarter 2024 earnings per share of -71 cents and revenue of $4,000.
Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.
Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data
- Significant Drug Effects: Alaunos Therapeutics' ALN1003 demonstrated a mean weight loss of up to -12.9% in diet-induced obesity mouse studies, indicating potential as a new treatment option for obesity.
- Liver Health Improvement: The drug reduced liver weight by 43% compared to untreated mice, highlighting its effectiveness and potential to lower the risk of obesity-related liver diseases.
- Biochemical Indicator Improvement: Long-term administration of ALN1003 was associated with significant reductions in ALT, AST, and ALP levels, along with a trend toward lower total bilirubin, suggesting its potential in improving metabolic health.
- Future Development Plans: The company plans to pursue additional financing to support ongoing preclinical work for ALN1003 and optimize manufacturing processes, ensuring drug efficacy and safety to pave the way for future IND applications.
Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential
- Significant Weight Loss: In the DIO mouse model, ALN1003-treated mice exhibited an average weight reduction of -12.9%, indicating the drug's potential efficacy in obesity treatment.
- Liver Health Improvement: ALN1003 reduced liver weight by 43% and lowered liver injury biomarkers such as ALT and AST, suggesting a positive impact on metabolic-associated liver disease.
- Reduced Food and Water Intake: The ALN1003 treatment group consumed significantly less food (347.5g/cage vs 425.0g/cage), which may correlate with the drug's weight loss mechanism, further supporting its potential as a non-hormonal treatment.
- Ongoing R&D Plans: Alaunos is focused on conducting additional preclinical studies and optimizing manufacturing processes to advance ALN1003, aiming to provide a new non-hormonal treatment option for obesity patients.
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.
Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
PMGC Capital's Acquisition: PMGC Capital LLC announced its acquisition of 83,500 shares (approximately 5.09%) in Alaunos Therapeutics, indicating a belief that the company is undervalued and has potential for growth.
Strategic Engagement Plans: PMGC Capital intends to engage with Alaunos' management to explore strategic opportunities such as mergers, acquisitions, or partnerships, while commending Alaunos for its financial stewardship.
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024
Earnings Report: Alaunos Therapeutics reported a second quarter 2024 earnings per share of -71 cents and revenue of $4,000.
Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.
